Equities

Doximity Inc

Doximity Inc

Actions
Health CareHealth Care Providers
  • Price (USD)58.25
  • Today's Change14.83 / 34.15%
  • Shares traded8.54m
  • 1 Year change+176.46%
  • Beta1.4420
Data delayed at least 15 minutes, as of Nov 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 08-Nov-24
Select bar for recommendation details.
Recommendations08-Nov-24
Buy3
Outperform5
Hold9
Sell1
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for Doximity Inc have a median target of 45.00, with a high estimate of 75.00 and a low estimate of 30.00. The median estimate represents a -22.75% decrease from the last price of 58.25.
High28.8%75.00
Med-22.7%45.00
Low-48.5%30.00

Earnings history & estimates in USD

On Nov 07, 2024, Doximity Inc reported 2nd quarter 2025 earnings of 0.300 per share. This result exceeded the 0.25 consensus of the 14 analysts covering the company and exceeded last year's 2nd quarter results by 36.36%.
The next earnings announcement is expected on Feb 06, 2025.
Average growth rate+9.29%
Doximity Inc reported annual 2024 earnings of 0.95 per share on May 16, 2024.
Average growth rate+9.58%
More ▼

Revenue history & estimates in USD

Doximity Inc had 2nd quarter 2025 revenues of 136.83m. This bettered the 127.15m consensus of the 15 analysts covering the company. This was 26.15% above the prior year's 2nd quarter results.
Average growth rate+5.41%
Doximity Inc had revenues for the full year 2024 of 475.42m. This was 13.45% above the prior year's results.
Average growth rate+17.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.